PSA Room - All PSAs

Site Body

Main Content

PULMONARY FIBROSIS FOUNDATION AND GENENTECH PARTNER TO LAUNCH A PUBLIC SERVICE ANNOUNCEMENT TO EDUCATE THE PUBLIC ON IDIOPATHIC PULMONARY FIBROSIS (IPF)

More than 100,000 Americans live with idiopathic pulmonary fibrosis (IPF) – a devastating disease caused by irreversible scarring of the lungs, which makes breathing difficult and prevents the rest of the body from getting enough oxygen.

More than 100,000 Americans live with idiopathic pulmonary fibrosis (IPF) – a devastating disease caused by irreversible scarring of the lungs, which makes breathing difficult and prevents the rest of the body from getting enough oxygen. IPF can be difficult to diagnose, and is often misdiagnosed, as it can seem similar to other lung disorders, such as COPD, and usually cannot be seen with a normal chest x-ray. Though the disease affects fewer people than other more common lung conditions such as asthma and COPD, the impact is significant. The median life expectancy for people with IPF is 3 - 5 years.

It is important to be educated about the health of your lungs, as well as symptoms that might indicate a serious disease. Early signs and symptoms of IPF may include a persistent cough; shortness of breath; and “Velcro-like” crackles deep in the lungs that a doctor can hear.

Diagnosing IPF is important as this serious disease is now a treatable one. Until October 2014, there were no medicines available to treat IPF, but now, there are medicines approved by the FDA for the treatment of IPF. Disease progression is unpredictable as IPF can progress quickly or slowly, and every patient is different. The medical community has not yet determined why some people develop IPF, while others with similar risk factors do not.

The Pulmonary Fibrosis Foundation and Genentech are partnering to launch a radio PSA to educate the public about IPF – what it is, its symptoms and why it is often misdiagnosed.

AUDIO PROVIDED BY:  Pulmonary Fibrosis Foundation

For further information: please visit: www.pulmonaryfibrosis.org.

FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE CONTACT: PSAS@multivu.com


print email rss